RS
LUCD icon

R Squared’s Lucid Diagnostics LUCD Stock Holding History

R Squared’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.7K Buy
30,587
+9,071
+42% +$9.78K 0.02% 470
2026
Q1 		$24.7K Buy
21,516
+3,077
+17% +$3.92K 0.01% 454
2025
Q4 		$20.1K Buy
+18,439
New +$20.6K 0.01% 493

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

R Squared's LUCD Position: Q2 2026 in Review

R Squared increased its Lucid Diagnostics (LUCD) stake by 42% in Q2 2026, buying an estimated $9.78K and bringing the position to 30,587 shares worth $32.7K. The position accounts for 0.02% of the portfolio, ranked #470.

R Squared first reported a position in LUCD in Q4 2025 and has held it in 3 quarters since. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • R Squared held 30,587 shares of Lucid Diagnostics worth $32.7K as of Q2 2026.
  • R Squared bought 9,071 Lucid Diagnostics shares in Q2 2026, an estimated $9.78K.
  • Lucid Diagnostics made up 0.02% of R Squared's portfolio in Q2 2026, its #470 holding.
  • R Squared first reported a position in Lucid Diagnostics in Q4 2025 and has held it in 3 quarters since.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.